Pediatr Crit Care Me
-
Pediatr Crit Care Me · Nov 2011
Case ReportsEndovascular treatment of near-fatal neonatal superior vena cava syndrome.
We describe the endovascular management of an 8-wk-old previously healthy female who developed superior vena cava syndrome secondary to Pseudomonas septic shock and disseminated intravascular coagulation. Doppler ultrasound confirmed near-total thrombotic occlusion of the superior vena cava and right internal jugular vein. She was taken emergently for cardiac catheterization, which confirmed the large superior vena cava thrombus extending into the right internal jugular vein and innominate vein with almost complete occlusion of the innominate vein. The superior vena cava to right atrium gradient was 14 mm Hg with very little antegrade flow into the right atrium, right femoral artery occlusion, and branch pulmonary artery emboli. Intervention involved serial balloon dilation inflations across the superior vena cava and innominate vein with improvement in the superior vena cava to right atrium gradient to 5 mm Hg and significant improvement in left ventricular function. Anticoagulation included heparin infusion for 48 hrs followed by enoxaparin for 1 month, alteplase for 48 hrs, eptifibatide (glycoprotein IIb/IIIa inhibitor) for 9 days followed by aspirin. ⋯ Daily head ultrasounds were performed without evidence of intracranial hemorrhage. All thromboses resolved within 3 wks. Her organ function recovered and she was discharged to home. The etiology of her colitis is still unknown. At 9-month follow-up, she was doing well with no residual organ dysfunction.
-
Pediatr Crit Care Me · Nov 2011
Case ReportsUse of tissue plasminogen activator to treat intracardiac thrombosis in extremely low-birth-weight infants.
Intracardiac thrombosis is a life-threatening complication of extreme prematurity. We describe the use of tissue plasminogen activator to treat intracardiac thrombosis in extremely low-birth-weight preterm infants. ⋯ Tissue plasminogen activator may safely be used to treat intracardiac thrombosis in extremely low-birth-weight preterm infants. Close monitoring of therapy is imperative. Further data are required to confirm the safety of tissue plasminogen activator in preterm infants.
-
Pediatr Crit Care Me · Nov 2011
Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
Critically ill children may present changes in pharmacokinetic parameters and may not reach effective concentrations of vancomycin with current dosages. The objective of this study is to calculate vancomycin pharmacokinetic parameters in critically ill children and to estimate area under the curve at 24 hrs/minimal inhibitory concentration reached for Staphylococcus aureus. ⋯ Critically ill children show changes in pharmacokinetic parameters. Serum concentration monitorization is necessary for dosage individualization. Most children do not reach an area under the curve at 24 hrs/minimal inhibitory concentration >400 with current dosage.
-
Pediatr Crit Care Me · Nov 2011
Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit.
Ethanol locks are being used to prevent and eradicate central venous catheter infections. This study describes the efficacy of ethanol locks in clearing central venous catheter infections in a pediatric intensive care unit. ⋯ Ethanol locks using 70% ethanol solution with dwell times as short as 4-6 hrs in conjunction with standard antibiotic therapy have 92% effective clearance of catheter-associated bloodstream infection and a 77% catheter salvage rate in our pediatric intensive care unit. The use of 70% ethanol locks appears to be well tolerated and represents a relatively inexpensive pharmacologic intervention that, along with systemic antibiotics, can help treat catheter-associated bloodstream infections and salvage central venous catheters.